ECSP099569A - Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehído - Google Patents

Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehído

Info

Publication number: ECSP099569A
Authority: EC; Ecuador
Prior art keywords: pirrolo; pirazol; carbaldehyde; amino; disease
Prior art date: 2007-02-07

Application number

EC2009009569A

Other languages

English (en)

Spanish (es)

Inventor

Min Teng

Seiji Nukui

Stephanie Anne Scales

Chunfeng Yin

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-07

Filing date

2009-08-07

Publication date

2009-09-29

2009-08-07 Application filed by Pfizer filed Critical Pfizer

2009-09-29 Publication of ECSP099569A publication Critical patent/ECSP099569A/es

Links

GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000027866 inflammatory disease Diseases 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
208000028867 ischemia Diseases 0.000 abstract 1
210000004185 liver Anatomy 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Dermatology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EC2009009569A 2007-02-07 2009-08-07 Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehído ECSP099569A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US88874907P	2007-02-07	2007-02-07
US98908607P	2007-11-19	2007-11-19
US2096508P	2008-01-14	2008-01-14

Publications (1)

Publication Number	Publication Date
ECSP099569A true ECSP099569A (es)	2009-09-29

Family

ID=39493354

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EC2009009569A ECSP099569A (es)	2007-02-07	2009-08-07	Nuevos derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehído

Country Status (19)

Country	Link
US (6)	US8183255B2 (pt)
EP (1)	EP2118112B1 (pt)
JP (1)	JP5161245B2 (pt)
KR (1)	KR101060892B1 (pt)
AP (1)	AP2009004958A0 (pt)
AU (1)	AU2008212625B2 (pt)
BR (1)	BRPI0807346B8 (pt)
CA (1)	CA2677572C (pt)
CR (1)	CR10968A (pt)
DO (1)	DOP2009000201A (pt)
EA (1)	EA017937B1 (pt)
EC (1)	ECSP099569A (pt)
IL (1)	IL200270A (pt)
MA (1)	MA31178B1 (pt)
MX (1)	MX2009008546A (pt)
NZ (1)	NZ578876A (pt)
TN (1)	TN2009000331A1 (pt)
WO (1)	WO2008096260A1 (pt)
ZA (1)	ZA200906032B (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA017937B1 (ru)	2007-02-07	2013-04-30	Пфайзер Инк.	ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС
EP2937345B1 (en)	2009-12-29	2018-03-21	Dana-Farber Cancer Institute, Inc.	Type ii raf kinase inhibitors
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012112674A2 (en) *	2011-02-15	2012-08-23	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
CN102093366B (zh) *	2011-03-04	2012-11-28	中国医学科学院医药生物技术研究所	双环氨基吡唑类化合物及其在抗柯萨奇病毒中的应用
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6106685B2 (ja)	2011-11-17	2017-04-05	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
US9321763B2 (en)	2012-04-04	2016-04-26	Rigel Pharmaceuticals, Inc.	Protein kinase C inhibitors and uses thereof
WO2013164323A1 (en) *	2012-05-03	2013-11-07	F. Hoffmann-La Roche Ag	Pyrazole aminopyrimidine derivatives as lrrk2 modulators for use in the treatment of parkinson's disease
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en)	2012-10-19	2020-08-25	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en)	2012-10-19	2018-06-19	Dana-Farber Cancer Institute, Inc.	Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US10154988B2 (en)	2012-11-14	2018-12-18	The Johns Hopkins University	Methods and compositions for treating schizophrenia
US9169249B2 (en)	2013-03-14	2015-10-27	Rigel Pharmaceuticals, Inc.	Protein kinase C inhibitors and uses thereof
AU2014337044A1 (en)	2013-10-18	2016-05-05	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
WO2015058126A1 (en)	2013-10-18	2015-04-23	Syros Pharmaceuticals, Inc.	Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
US9814716B2 (en)	2014-05-23	2017-11-14	Mingsight Pharmaceuticals, Inc.	Treatment of autoimmune disease
US10870651B2 (en)	2014-12-23	2020-12-22	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh)	2015-03-27	2021-08-03	达纳-法伯癌症研究所股份有限公司	细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en)	2015-09-09	2017-03-16	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CA3005723A1 (en) *	2015-11-20	2017-05-26	Mingsight Pharmaceuticals, Inc.	Treatment of autoimmune disease
CN106727582B (zh) *	2015-11-20	2020-06-12	深圳明赛瑞霖药业有限公司	自身免疫疾病的治疗
EP3484477B1 (en)	2016-07-14	2023-09-13	Mingsight Pharmaceuticals, Inc.	Treatment of cancer
US11104679B2 (en)	2017-05-25	2021-08-31	Mingsight Pharmaceuticals, Inc.	PKC inhibitor solid state forms
WO2019072942A1 (en)	2017-10-11	2019-04-18	F. Hoffmann-La Roche Ag	BICYCLIC COMPOUNDS FOR USE AS INHIBITORS OF KINASE RIP1
WO2019143818A1 (en) *	2018-01-17	2019-07-25	Mingsight Pharmaceuticals, Inc.	Combination therapy for the treatment of cancer
EP3810132A4 (en)	2018-06-25	2022-06-22	Dana-Farber Cancer Institute, Inc.	TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN113164477A (zh)	2018-12-14	2021-07-23	达纳-法伯癌症研究所股份有限公司	C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (en) *	2018-12-28	2022-09-07	Dana-Farber Cancer Institute, Inc.	CYCLIN DEPENDENT KINASE 7 INHIBITORS AND USES THEREOF
WO2022261214A1 (en) *	2021-06-09	2022-12-15	Mingsight Pharmaceuticals, Inc.	Compositions comprising pkc-beta inhibitors and processes for the preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2416527C (en) *	2000-08-10	2009-12-22	Pharmacia Italia S.P.A.	Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
UA81790C2 (uk)	2002-12-19	2008-02-11	Фармация Италия С.П.А.	Заміщені піролопіразольні похідні як інгібітори кінази
CA2593428C (en) *	2005-01-10	2012-04-17	Pfizer Inc.	Pyrrolopyrazoles, potent kinase inhibitors
EA017937B1 (ru)	2007-02-07	2013-04-30	Пфайзер Инк.	ПРОИЗВОДНЫЕ 3-АМИНОПИРРОЛО[3,4-c]ПИРАЗОЛ-5(1H,4H,6H)-КАРБАЛЬДЕГИДА В КАЧЕСТВЕ ИНГИБИТОРОВ РКС

2008
- 2008-02-04 EA EA200970670A patent/EA017937B1/ru not_active IP Right Cessation
- 2008-02-04 KR KR1020097018673A patent/KR101060892B1/ko active Active
- 2008-02-04 NZ NZ578876A patent/NZ578876A/xx unknown
- 2008-02-04 US US12/523,965 patent/US8183255B2/en active Active
- 2008-02-04 AU AU2008212625A patent/AU2008212625B2/en active Active
- 2008-02-04 EP EP08702370.1A patent/EP2118112B1/en active Active
- 2008-02-04 AP AP2009004958A patent/AP2009004958A0/xx unknown
- 2008-02-04 WO PCT/IB2008/000297 patent/WO2008096260A1/en not_active Ceased
- 2008-02-04 JP JP2009548766A patent/JP5161245B2/ja active Active
- 2008-02-04 CA CA2677572A patent/CA2677572C/en active Active
- 2008-02-04 BR BRPI0807346A patent/BRPI0807346B8/pt active IP Right Grant
- 2008-02-04 MX MX2009008546A patent/MX2009008546A/es active IP Right Grant
2009
- 2009-08-05 TN TNP2009000331A patent/TN2009000331A1/fr unknown
- 2009-08-06 IL IL200270A patent/IL200270A/en not_active IP Right Cessation
- 2009-08-06 CR CR10968A patent/CR10968A/es unknown
- 2009-08-07 MA MA32158A patent/MA31178B1/fr unknown
- 2009-08-07 DO DO2009000201A patent/DOP2009000201A/es unknown
- 2009-08-07 EC EC2009009569A patent/ECSP099569A/es unknown
- 2009-08-31 ZA ZA2009/06032A patent/ZA200906032B/en unknown
2012
- 2012-04-18 US US13/450,388 patent/US8877761B2/en active Active
2014
- 2014-10-03 US US14/506,470 patent/US9518060B2/en active Active
2016
- 2016-12-12 US US15/376,279 patent/US10316045B2/en active Active
2019
- 2019-04-17 US US16/387,369 patent/US11220518B2/en active Active
2021
- 2021-12-01 US US17/539,948 patent/US11780853B2/en active Active

Also Published As

Publication number	Publication date
US20120202809A1 (en)	2012-08-09
WO2008096260A1 (en)	2008-08-14
CR10968A (es)	2009-08-27
NZ578876A (en)	2012-12-21
AU2008212625A1 (en)	2008-08-14
EA200970670A1 (ru)	2010-02-26
US10316045B2 (en)	2019-06-11
US20170217991A1 (en)	2017-08-03
EP2118112A1 (en)	2009-11-18
BRPI0807346B8 (pt)	2021-05-25
US8877761B2 (en)	2014-11-04
US8183255B2 (en)	2012-05-22
IL200270A0 (en)	2010-04-29
ZA200906032B (en)	2013-03-27
JP2010518069A (ja)	2010-05-27
CA2677572C (en)	2012-12-18
US11780853B2 (en)	2023-10-10
KR20090119883A (ko)	2009-11-20
MX2009008546A (es)	2009-10-08
BRPI0807346A2 (pt)	2016-07-26
EP2118112B1 (en)	2015-07-08
US20220089613A1 (en)	2022-03-24
EA017937B1 (ru)	2013-04-30
AU2008212625B2 (en)	2012-07-19
IL200270A (en)	2014-07-31
TN2009000331A1 (fr)	2010-12-31
US11220518B2 (en)	2022-01-11
HK1139130A1 (en)	2010-09-10
AP2009004958A0 (en)	2009-08-31
US20100130501A1 (en)	2010-05-27
US9518060B2 (en)	2016-12-13
BRPI0807346B1 (pt)	2020-01-07
CA2677572A1 (en)	2008-08-14
KR101060892B1 (ko)	2011-08-31
MA31178B1 (fr)	2010-02-01
US20200002359A1 (en)	2020-01-02
DOP2009000201A (es)	2009-08-31
US20150099743A1 (en)	2015-04-09
JP5161245B2 (ja)	2013-03-13

Publication	Publication Date	Title
DOP2009000201A (es)	2009-08-31	Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h, 4h, 6h)carbaldehido como inhibidores pkc
WO2008125945A3 (en)	2009-03-12	3-amido-pyrrolo [3, 4-c] pyrazole-5 (1h, 4h, 6h) carbaldehyde derivatives as inhibitors of protein kinase c
UY31545A1 (es)	2009-08-03	Nuevos derivados de 2-carboxamida cianoaminourea, sus sales y profarmacos farmacéuticamente aceptables, procesos de preparacion y aplicaciones
ECSP066730A (es)	2006-10-31	Compuestos y procedimientos para uso
CR9954A (es)	2008-05-28	Derivados de pirazina
CU23105A3 (es)	2006-01-20	DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
UY29503A1 (es)	2006-11-30	Derivados de amida sustituida y metodos de uso
PA8627201A1 (es)	2005-12-23	Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY27872A1 (es)	2003-12-31	Inhibidores de caspasa y usos de los mismos.
CR11627A (es)	2010-11-22	Derivados heterociclicos fusionados y metodos de uso como inhibidores c-met
UY30408A1 (es)	2008-01-31	Derivados sustituidos del acetato de 8-(4-metoxifenil)-2,3,4,8-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones
DOP2016000276A (es)	2017-02-28	2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
AR087915A1 (es)	2014-04-23	N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
UY30377A1 (es)	2008-01-02	Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
PA8604201A1 (es)	2004-12-16	Derivados de 2-amino-piridina utiles para el tratamiento de enfermedades
MX2020004283A (es)	2021-10-21	Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
ECSP088569A (es)	2008-08-29	Nuevos derivados de furopirimidina acíclicos sustituidos y uso de los mismos para el tratamiento de enfermedades cardiovasculares
UY32744A (es)	2011-01-31	Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
UY39181A (es)	2021-11-30	COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
DOP2024000239A (es)	2024-12-30	Compuestos amido heteroaromáticos útiles en el tratamiento de enfermedades hepáticas
CO6321280A2 (es)	2011-09-20	Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
UA96618C2 (en)	2011-11-25	3-amino-pyrrolo[3,4-c] pyrazole- 5 (1h, 4h, 6h) carbaldehyde derivatives as pkc inhibitors
GT200700097A (es)	2009-06-04	Nuevos derivados de fenilpiridinilpiperazina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
PA8627001A1 (es)	2006-05-16	Compuestos para el tratamiento de enfermedades
UY29065A1 (es)	2006-02-24	Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.